Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eton Pharmaceutcials Inc (ETON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 137,342
  • Shares Outstanding, K 17,608
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.65
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.09 +12.13%
on 03/08/19
8.11 -1.97%
on 03/12/19
+0.35 (+4.61%)
since 02/25/19
3-Month
5.70 +39.47%
on 01/07/19
8.11 -1.97%
on 03/12/19
+1.95 (+32.50%)
since 12/24/18

Most Recent Stories

More News
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the fourth quarter and full...

ETON : 7.95 (+1.92%)
Eton Pharmaceuticals Submits New Drug Application for DS-200

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process....

ETON : 7.95 (+1.92%)
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

BHC : 24.14 (-2.23%)
GSK : 41.21 (-0.10%)
ETON : 7.95 (+1.92%)
BMY : 47.49 (-1.39%)
Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer,...

ETON : 7.95 (+1.92%)
Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies

If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind

ETON : 7.95 (+1.92%)
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates

Transaction adds an additional potential 2019 product launch to Eton's pipeline

ETON : 7.95 (+1.92%)
Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a licensing and...

ETON : 7.95 (+1.92%)
Eton Pharmaceuticals Reports Third Quarter Results and Business Update

Licensed High-Value Injectable Product Candidate

ETON : 7.95 (+1.92%)
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500(TM)

Imprimis attributes growth to its vision of making sure patients have access to high quality affordable medications

IMMY : 5.69 (+9.63%)
ETON : 7.95 (+1.92%)
Trade ETON with:

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

2nd Resistance Point 8.07
1st Resistance Point 8.01
Last Price 7.95
1st Support Level 7.83
2nd Support Level 7.70

See More

52-Week High 8.11
Last Price 7.95
Fibonacci 61.8% 7.19
Fibonacci 50% 6.90
Fibonacci 38.2% 6.62
52-Week Low 5.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar